Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Werte in diesem Artikel
CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 10:30 AM EST.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 6 months following the conference.
The Piper Sandler Healthcare Conference will take place December 3-5, 2024 in New York.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-302315009.html
SOURCE Akebia Therapeutics, Inc.
Ausgewählte Hebelprodukte auf Akebia Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Akebia Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Akebia Therapeutics Inc
Analysen zu Akebia Therapeutics Inc
Datum | Rating | Analyst | |
---|---|---|---|
06.08.2019 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
11.07.2019 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
10.08.2018 | Akebia Therapeutics Buy | Needham & Company, LLC | |
06.06.2018 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
07.12.2017 | Akebia Therapeutics Buy | BTIG Research |
Datum | Rating | Analyst | |
---|---|---|---|
06.08.2019 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
11.07.2019 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
10.08.2018 | Akebia Therapeutics Buy | Needham & Company, LLC | |
06.06.2018 | Akebia Therapeutics Buy | H.C. Wainwright & Co. | |
07.12.2017 | Akebia Therapeutics Buy | BTIG Research |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | Akebia Therapeutics Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Akebia Therapeutics Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen